Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the …

Corresponding Author

Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Correspondence: Dickran Kazandjian, M.D., Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20854, USA. Telephone: 718‐795‐6027; e‐mail: kazandjiandg@mail.nih.govSearch for more papers by this author

Published at Mon, 08 Feb 2021 09:55:58 +0000